Optimizing the treatment regimen for targeted alpha therapy of mCRPC with 225Ac-PSMA-617

KRATOCHWIL, Clemens; RATHKE, H; BRUCHERTSEIFER, Frank; GIESEL, Frederik; HABERKORN, Uwe; MORGENSTERN, Alfred

doi:10.1007/s00259-018-4148-3

An official website of the European Union How do you know?

Optimizing the treatment regimen for targeted alpha therapy of mCRPC with 225Ac-PSMA-617

PSMA-targeting alpha-therapy (PSMA-TAT) of mCRPC with 225Ac-PSMA-617 (8 MBq, 3 cycles, 8 week intervals) already demonstrated promising anti-tumor activity, but also induced severe and often irreversible xerostomia (1,2). Our objective was to optimize the treatment protocol to improve tolerability.

KRATOCHWIL Clemens; RATHKE H; BRUCHERTSEIFER Frank; GIESEL Frederik; HABERKORN Uwe; MORGENSTERN Alfred;

2018-11-12

SPRINGER

JRC111747

1619-7070 (online),

https://publications.jrc.ec.europa.eu/repository/handle/JRC111747,

10.1007/s00259-018-4148-3 (online),

Language	Citation

Name	Country	City	Type

Datasets

ID	Title	Public URL

Dataset collections

ID	Acronym	Title	Public URL

Scripts / source codes

Description	Public URL

Additional supporting files

File name	Description	File type

Show metadata record Copy citation url to clipboard Download BibTeX

Items published in the JRC Publications Repository are protected by copyright, with all rights reserved, unless otherwise indicated. Additional information: https://ec.europa.eu/info/legal-notice_en#copyright-notice